Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
T-LGL
MCID: TCL002
MIFTS: 49

T-Cell Large Granular Lymphocyte Leukemia (T-LGL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for T-Cell Large Granular Lymphocyte Leukemia

About this section

MalaCards integrated aliases for T-Cell Large Granular Lymphocyte Leukemia:

Name: T-Cell Large Granular Lymphocyte Leukemia 12 52 58 15 71
Proliferation of Large Granular Lymphocytes 52 58
T-Cell Lgl Leukemia 52 58
T-Lgl 52 58
Large Cell Granular Lymphogenous Leukemia 52
Leukemia, Large Granular Lymphocytic 71
Large Granular Lymphocytic Leukemia 12
Leukemia Lymphocytic Large Granular 54
T-Lgl Leukemia 52

Characteristics:

Orphanet epidemiological data:

58
t-cell large granular lymphocyte leukemia
Prevalence: 1-9/1000000 (Europe); Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
Orphanet: 58  
Rare haematological diseases
Rare immunological diseases


External Ids:

Disease Ontology 12 DOID:0050751
MESH via Orphanet 44 D054066
UMLS via Orphanet 72 C1955861 C2930809
Orphanet 58 ORPHA86872
UMLS 71 C1522378 C1955861
Sources

Summaries for T-Cell Large Granular Lymphocyte Leukemia

About this section
NIH Rare Diseases : 52 T-cell large granular lymphocyte leukemia is a rare cancer of a type of white blood cells called lymphocytes. T-cell large granular lymphocyte leukemia causes a slow increase in white blood cells called T lymphocytes, or T cells, which originate in the lymph system and bone marrow and help to fight infection. This disease usually affects people in their sixties. Symptoms include anemia ; low levels of platelets (thrombocytopenia ) and infection-fighting neutrophils (neutropenia ) in the blood; and an enlarged spleen . About one-third of patients are asymptomatic at the time of diagnosis. The exact cause of LGL leukemia is unknown. Doctors can diagnose this disease through a bone marrow biopsy , or by using a specialized technique in which various types of blood or bone marrow cells are separated, identified, and counted.

MalaCards based summary : T-Cell Large Granular Lymphocyte Leukemia, also known as proliferation of large granular lymphocytes, is related to large granular lymphocyte leukemia and red cell aplasia. An important gene associated with T-Cell Large Granular Lymphocyte Leukemia is STAT3 (Signal Transducer And Activator Of Transcription 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cefepime and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A chronic lymphocytic leukemia that exhibits an unexplained, chronic (> 6 months) elevation in large granular lymphocytes (LGLs) in the peripheral blood.

Wikipedia : 74 Large granular lymphocytic (LGL) leukemia is a chronic lymphoproliferative disorder that exhibits an... more...

Sources

Related Diseases for T-Cell Large Granular Lymphocyte Leukemia

About this section

Diseases related to T-Cell Large Granular Lymphocyte Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 253)
# Related Disease Score Top Affiliating Genes
1 large granular lymphocyte leukemia 33.1 STAT5B STAT3 KLRD1 IL2RA CSF2
2 red cell aplasia 31.4 STAT3 IL2RA IL2
3 pure red-cell aplasia 31.3 STAT3 IL2RA IL2
4 lymphoproliferative syndrome 30.9 STAT3 IL2RA IL2 FASLG
5 chronic graft versus host disease 30.7 MICA IL2RA
6 chronic nk-cell lymphocytosis 30.2 NCAM1 KLRD1 KIR2DL3 KIR2DL1
7 anaplastic large cell lymphoma 30.0 STAT3 IL2RA GZMB
8 virus associated hemophagocytic syndrome 29.9 IL2RB IL2
9 hairy cell leukemia 29.9 IL2RB IL2RA IL2
10 candidiasis 29.9 STAT3 IL2 CSF2
11 graft-versus-host disease 29.8 IL2 GZMB FASLG
12 tropical spastic paraparesis 29.7 KLRK1 IL2RB IL2RA IL2
13 aggressive nk-cell leukemia 29.6 STAT3 NCAM1 KLRD1 GZMB FASLG
14 lymphoma, hodgkin, classic 29.5 IL2RA IL2 GZMB CSF2
15 aspergillosis 29.4 STAT3 IL18 CSF2
16 hemophagocytic lymphohistiocytosis 29.4 IL2RA IL18 GZMB
17 leukemia, chronic lymphocytic 29.3 STAT5B STAT3 NCAM1 IL2RA IL2 CSF2
18 thrombocytopenia 29.3 STAT3 IL2 IL18 FASLG CSF2
19 autoimmune lymphoproliferative syndrome 29.2 STAT3 IL2RA IL2 GZMB FASLG
20 t-cell leukemia 29.2 STAT5B IL2RB IL2RA IL2 CSF2
21 peripheral t-cell lymphoma 29.2 STAT3 NCAM1 IL2RB IL2 GZMB
22 cutaneous t cell lymphoma 29.2 STAT3 IL2RB IL2RA IL2 GZMB
23 myelodysplastic syndrome 29.0 STAT5B STAT3 KLRK1 IL2 GZMB FASLG
24 common variable immunodeficiency 28.9 STAT3 IL2RB IL2RA IL2 GZMB
25 autoimmune disease 28.9 STAT3 KLRK1 IL2RA IL2 IL18 FASLG
26 severe combined immunodeficiency 28.9 STAT5B IL2RB IL2RA IL2 CSF2
27 juvenile rheumatoid arthritis 28.8 IL2RB IL2RA IL2 IL18
28 b-cell expansion with nfkb and t-cell anergy 28.8 IL2RB IL2RA IL2 GZMB FASLG
29 sarcoidosis 1 28.8 IL2RB IL2RA IL2 IL18
30 aplastic anemia 28.7 STAT3 IL2RA IL2 IL18 FASLG CSF2
31 viral infectious disease 28.7 KLRK1 IL2RA IL2 IL18 GZMB
32 lymphadenitis 28.7 STAT3 IL2RB IL2RA IL18 FASLG
33 lymphopenia 28.6 IL2RB IL2RA IL2 IL18 FASLG
34 renal cell carcinoma, nonpapillary 28.6 STAT3 IL2RB IL2RA IL2 FASLG CSF2
35 rheumatoid arthritis 28.2 IL2RB IL2RA IL2 IL18 FASLG CSF2
36 leukemia, acute myeloid 28.2 STAT5B STAT3 NCAM1 KLRK1 KLRD1 KIR2DL3
37 lymphoma, non-hodgkin, familial 28.1 STAT3 NCAM1 IL2RB IL2RA IL2 GZMB
38 myeloma, multiple 27.9 STAT5B STAT3 NCAM1 MICA KLRK1 KIR2DL1
39 multiple sclerosis 27.8 STAT3 IL2RB IL2RA IL2 IL18 FASLG
40 systemic lupus erythematosus 27.6 STAT3 IL2RB IL2RA IL2 IL18 FASLG
41 celiac disease 1 27.4 NCAM1 MICA KLRK1 KLRD1 IL2RB IL2RA
42 lymphocytic leukemia 11.1
43 leukemia 10.9
44 neutropenia 10.9
45 splenomegaly 10.7
46 lymphoma 10.5
47 pancytopenia 10.5
48 hepatosplenic t-cell lymphoma 10.4
49 autoimmune enteropathy 10.4 STAT3 IL2RA
50 felty syndrome 10.4

Graphical network of the top 20 diseases related to T-Cell Large Granular Lymphocyte Leukemia:



Diseases related to T-Cell Large Granular Lymphocyte Leukemia
Sources

Symptoms & Phenotypes for T-Cell Large Granular Lymphocyte Leukemia

About this section

GenomeRNAi Phenotypes related to T-Cell Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

26 (show all 30)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.2 STAT5B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.2 IL18
3 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.2 KIR2DL1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.2 IL2RB
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.2 STAT5B
6 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.2 STAT5B
7 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.2 IL18
8 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.2 STAT5B
9 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.2 KIR2DL1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.2 KIR2DL1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.2 IL18
12 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.2 KIR2DL1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.2 KIR2DL1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.2 IL18 KIR2DL1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.2 STAT5B
16 Increased shRNA abundance (Z-score > 2) GR00366-A-182 10.2 IL18
17 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.2 KIR2DL1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.2 KIR2DL1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.2 IL2RB STAT5B
20 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.2 KIR2DL1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.2 STAT5B
22 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.2 IL18
23 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.2 IL18
24 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.2 IL2RB STAT5B
25 Increased shRNA abundance (Z-score > 2) GR00366-A-5 10.2 IL18 IL2RB KIR2DL1 STAT5B
26 Increased shRNA abundance (Z-score > 2) GR00366-A-6 10.2 IL18
27 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.2 IL2RB
28 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.2 IL18
29 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.2 KIR2DL1
30 Reduced mammosphere formation GR00396-S 9.17 FASLG IL15RA IL2RA KLRD1 KLRK1 NCAM1

MGI Mouse Phenotypes related to T-Cell Large Granular Lymphocyte Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.81 CSF2 FASLG IL15RA IL2 IL2RA IL2RB
2 hematopoietic system MP:0005397 9.7 CSF2 FASLG GZMA IL15RA IL18 IL2
3 immune system MP:0005387 9.4 CSF2 FASLG GZMA IL15RA IL18 IL2
Sources

Drugs & Therapeutics for T-Cell Large Granular Lymphocyte Leukemia

About this section

Drugs for T-Cell Large Granular Lymphocyte Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 195)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
2
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
3
Ofloxacin Approved Phase 3 82419-36-1 4583
4
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
5
Ondansetron Approved Phase 3 99614-02-5 4595
6
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
7
Dalteparin Approved Phase 3 9005-49-6
8
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
9
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
12
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
13
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
14 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
15 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
16 Anesthetics, Dissociative Phase 3
17 Liver Extracts Phase 3
18 Analgesics Phase 3
19 Cola Phase 3
20 Antipsychotic Agents Phase 3
21 Central Nervous System Depressants Phase 3
22 Tranquilizing Agents Phase 3
23 Analgesics, Opioid Phase 3
24 Neurotransmitter Agents Phase 3
25 Psychotropic Drugs Phase 3
26 Antipruritics Phase 3
27 Anti-Anxiety Agents Phase 3
28 Serotonin Agents Phase 3
29 Serotonin Antagonists Phase 3
30 Hematinics Phase 3
31 Epoetin alfa Phase 3 113427-24-0
32 Heparin, Low-Molecular-Weight Phase 3
33 Narcotics Phase 3
34 Excitatory Amino Acid Antagonists Phase 3
35 Excitatory Amino Acids Phase 3
36 Anesthetics Phase 3
37 Adjuvants, Anesthesia Phase 3
38 Anesthetics, General Phase 3
39 Anesthetics, Intravenous Phase 3
40 Antiparasitic Agents Phase 3
41 Antiprotozoal Agents Phase 3
42 ferric gluconate Phase 3
43 Iron Supplement Phase 3
44 Ferric Compounds Phase 3
45 Liposomal amphotericin B Phase 3
46
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
47
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
48
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
49
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
50
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0

Interventional clinical trials:

(show top 50) (show all 123)
# Name Status NCT ID Phase Drugs
1 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
2 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
4 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
5 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
6 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
7 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
8 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
9 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
10 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
11 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
12 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
13 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
14 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
16 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
17 Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia Completed NCT00031980 Phase 2 cyclosporine
18 A Multicenter Study to Assess the Efficacy of 506U78 in Patients With Chronic Lymphocytic Leukemia Who Are Refractory to Fludarabine and Alkylator Therapy Completed NCT00003635 Phase 2 nelarabine
19 Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia Completed NCT00278213 Phase 2 cyclophosphamide;fludarabine phosphate;mitoxantrone hydrochloride
20 OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER Completed NCT00002504 Phase 2
21 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
22 Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy Completed NCT00255749 Phase 2
23 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
24 Ex Vivo Expanded Megakaryocytes for Supportive Care of Breast Cancer Patients: A Phase I/II Study Completed NCT00006225 Phase 1, Phase 2
25 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
26 A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
27 An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune T-Lymphocytes Derived From a Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases Completed NCT00002663 Phase 1, Phase 2
28 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
29 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
30 A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
31 RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
32 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
33 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
34 Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial Completed NCT00104858 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
35 A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T‑Cell Lymphoma Recruiting NCT03239392 Phase 1, Phase 2 BNZ132-1-40
36 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
37 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
38 Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia Recruiting NCT01976182 Phase 2 Methotrexate;Cyclophosphamide
39 Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Alemtuzumab (Campath) Active, not recruiting NCT00345345 Phase 2
40 Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies. Active, not recruiting NCT01609816 Phase 1, Phase 2 Dasatinib
41 Phase I/II Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies. Active, not recruiting NCT01643603 Phase 1, Phase 2 Dasatinib
42 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Active, not recruiting NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
43 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Active, not recruiting NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
44 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Active, not recruiting NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
45 First Line Therapy With Methotrexate (MTX) and Second Line Therapy With Fludarabine of Patients With T-Cell Large Granular Lymphocyte Leukemia (T-LGL) Terminated NCT00278265 Phase 2 MTX followed by fludarabine
46 Phase II Pilot Study Of Alemtuzumab In Patients With Low Or INT-1 Risk Myelodysplastic Syndrome (MDS), Aplastic Anemia (AA), Or T-Cell Large Granular Lymphocytic Leukemia (T-LGL) Terminated NCT01191749 Phase 2 Alemtuzumab
47 A Phase II Study of Sunitinib Malate in Idiopathic Myelofibrosis Terminated NCT00387426 Phase 2 sunitinib malate
48 A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia Terminated NCT00360776 Phase 2 tipifarnib
49 Microarray Analysis of the Effect of Cyclosporine Therapy on Gene Expression Patterns in Large Granular Lymphocytic Leukemia Terminated NCT00363779 Phase 2 Cyclosporine
50 A Phase II Study of Initial Treatment With Methotrexate in Large Granular Lymphocytic (LGL) Leukemia Terminated NCT00003910 Phase 2 Cyclophosphamide;Methotrexate;Prednisone

Search NIH Clinical Center for T-Cell Large Granular Lymphocyte Leukemia

Sources

Genetic Tests for T-Cell Large Granular Lymphocyte Leukemia

About this section
Sources

Anatomical Context for T-Cell Large Granular Lymphocyte Leukemia

About this section

MalaCards organs/tissues related to T-Cell Large Granular Lymphocyte Leukemia:

40
T Cells, Bone, Bone Marrow, B Cells, Spleen, Neutrophil, Myeloid
Sources

Publications for T-Cell Large Granular Lymphocyte Leukemia

About this section

Articles related to T-Cell Large Granular Lymphocyte Leukemia:

(show top 50) (show all 293)
# Title Authors PMID Year
1
Inclusion-Body Myositis And Primary Sjögren Syndrome: Mechanisms For Shared Etiologies. 61
32035011 2020
2
Retroviral sero-reactivity in LGL leukaemia patients and family members. 61
31608437 2020
3
Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: A single-institution experience. 61
32035354 2020
4
Causes of double-negative T-cell lymphocytosis in children and adults. 61
31810993 2019
5
Choroidal Infiltration as First Clinical Manifestation of T-cell Large Granular Lymphocyte (T-LGL) Leukemia. 61
31577464 2019
6
Accelerated analysis of Boolean gene regulatory networks via reconfigurable hardware. 61
31494553 2019
7
STAT5BN642H drives transformation of NKT cells: a novel mouse model for CD56+ T-LGL leukemia. 61
30967617 2019
8
T cell large granular lymphocyte leukemia and chronic NK lymphocytosis. 61
31585621 2019
9
T-cell large granular lymphocyte leukemia in solid organ transplant recipients: case series and review of the literature. 61
31250283 2019
10
Recurrent anti-GBM disease with T-cell large granular lymphocytic leukemia: A case report. 61
31374037 2019
11
Skewing of the T-cell receptor repertoire in patients receiving rituximab after allogeneic hematopoietic cell transplantation: what lies beneath? 61
30652530 2019
12
Identification of regulatory variables for state transition of biological networks. 61
31071365 2019
13
Scalable optimal Bayesian classification of single-cell trajectories under regulatory model uncertainty. 61
31189480 2019
14
[CD4(-)/CD8(-)/CD56(+)/TCRγδ(+) T-cell large granular lymphocyte leukemia presenting as aplastic anemia: a case report and literature review]. 61
31340629 2019
15
IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability. 61
30353031 2019
16
Immune dysregulation: EBV+ DLBCL and HLH in a patient with T-LGL. 61
30975643 2019
17
T-cell large granular lymphocyte leukemia transfomation into aggressive T-cell lymphoma: a report of two cases with molecular characterization. 61
30573508 2019
18
Edgetic perturbations to eliminate fixed-point attractors in Boolean regulatory networks. 61
30823730 2019
19
[Successful treatment of pure red cell aplasia with cyclosporin in a patient with T-cell large granular lymphocytic leukemia harboring the STAT3 D661V mutation]. 61
30726823 2019
20
T-cell large granular lymphocytic (LGL) leukemia consists of CD4+/CD8dim and CD4-/CD8+ LGL populations in association with immune thrombocytopenia, autoimmune neutropenia, and monoclonal B-cell lymphocytosis. 61
31866622 2019
21
A Case of T-Cell Large Granular Lymphocytic Leukemia and Renal Immunoglobulin Heavy Chain Amyloidosis. 61
30631033 2019
22
Complete remission of agranulocytosis after splenectomy in a variant form of T-cell large granular lymphocyte leukemia. 61
29963929 2019
23
[Hepatocellular failure revealing T-cell large granular lymphocyte leukemia: Morocco case study and literature review]. 61
31934260 2019
24
Prevalence and Characteristics of Persistent Clonal T Cell Large Granular Lymphocyte Expansions in Rheumatoid Arthritis: A Comprehensive Analysis of 529 Patients. 61
29938921 2018
25
Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes. 61
30455079 2018
26
Does it take three to tango? An unsuspected multimorbidity of CD8+ T cell lymphoproliferative disorder, malaria, and EBV infection. 61
30290813 2018
27
Large granular lymphocytic leukemia CD3-CD56-: a challenge for the biologist and the physician. 61
30078779 2018
28
Management of T-cell large granular lymphocyte leukemia and concurrent retroperitoneal liposarcoma. 61
30057739 2018
29
Pure red cell aplasia with t-cell large granular lymphocytic leukemia. 61
29921385 2018
30
Mutations in the signal transducer and activator of transcription family of genes in cancer. 61
29417693 2018
31
Donor derived T-cell large granular lymphocyte leukemia after cord blood transplant for pediatric T-cell lymphoblastic leukemia. 61
29269802 2018
32
T-Cell Large Granular Lymphocytic Leukemia and Coexisting B-Cell Lymphomas: A Study From the Bone Marrow Pathology Group. 61
29365010 2018
33
Next-Generation Sequencing Analysis of the Human TCRγδ+ T-Cell Repertoire Reveals Shifts in Vγ- and Vδ-Usage in Memory Populations upon Aging. 61
29559980 2018
34
Dysregulation of the IFN-γ-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. 61
29474442 2018
35
Successful treatment of cerebral aspergillosis: case report of a patient with T-cell large granular lymphocytic leukemia (T-LGL). 61
29281994 2017
36
Comparison of T lymphocyte subsets in aplastic anemia and hypoplastic myelodysplastic syndromes. 61
28935248 2017
37
STAT3 mutation impacts biological and clinical features of T-LGL leukemia. 61
28977911 2017
38
Protothecosis in a patient with T cell lymphocytic leukemia. 61
28554708 2017
39
Vitamin D decreases STAT phosphorylation and inflammatory cytokine output in T-LGL leukemia. 61
27715403 2017
40
Metronomic regimen as an effective treatment for aggressive T-LGL leukemia with central nervous system infiltration: clinical experience and review of literature. 61
28427176 2017
41
Correlations in the degeneracy of structurally controllable topologies for networks. 61
28401952 2017
42
A screening method with lymphocyte percentage and proportion of granular lymphocytes in the peripheral blood for large granular lymphocyte (LGL) leukemia. 61
27686672 2017
43
Distinguishing Between Hepatosplenic T-cell Lymphoma and γδ T-cell Large Granular Lymphocytic Leukemia: A Clinicopathologic, Immunophenotypic, and Molecular Analysis. 61
27755009 2017
44
Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias. 61
28717070 2017
45
Concurrent STAT3, DNMT3A, and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential. 61
27761930 2017
46
Dysregulated signaling, proliferation and apoptosis impact on the pathogenesis of TCRγδ+ T cell large granular lymphocyte leukemia. 61
28407008 2017
47
[Successful treatment of large granular lymphocytic leukemia accompanied by refractory anemia with alemtuzumab]. 61
29332872 2017
48
Late Graft Rejection in Association With T-Large Granular Lymphocyte Expansion of Recipient Origin After Human Leukocyte Antigen-Haploidentical Stem Cell Transplantation: A Case Report. 61
27932186 2016
49
T-Cell Large Granular Lymphocyte Leukemia in the Lower Eyelid. 61
25198396 2016
50
High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. 61
27697773 2016
Sources

Variations for T-Cell Large Granular Lymphocyte Leukemia

About this section
Sources

Expression for T-Cell Large Granular Lymphocyte Leukemia

About this section
Search GEO for disease gene expression data for T-Cell Large Granular Lymphocyte Leukemia.
Sources

Pathways for T-Cell Large Granular Lymphocyte Leukemia

About this section

Pathways related to T-Cell Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.95 STAT5B STAT3 NCAM1 MICA KLRK1 KLRD1
2
ERK Signaling 63
Show member pathways
 13.79 STAT5B STAT3 IL2RB IL2RA IL2 IL18
3
PEDF Induced Signaling 63
Show member pathways
 13.65 STAT5B STAT3 IL2RB IL2RA IL2 IL18
4
Akt Signaling 63
Show member pathways
 13.4 STAT5B STAT3 IL2RB IL2RA IL2 IL18
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.33 STAT5B STAT3 NCAM1 IL2RB IL2RA IL2
6
PAK Pathway 63
Show member pathways
 13.27 IL2RB IL2RA IL2 IL18 IL15RA FASLG
7
Pathways in cancer 36
12.85 STAT5B STAT3 IL2RB IL2RA IL2 IL15RA
8
Measles 36
Show member pathways
 12.83 STAT5B STAT3 IL2RB IL2RA IL2 IL18
9
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.77 STAT5B STAT3 IL2RB IL2RA IL2 IL15RA
10
Allograft rejection 1 36
Show member pathways
 12.76 MICA KLRD1 KIR2DL3 KIR2DL1 IL2RA IL2
11
Th17 cell differentiation 36
Show member pathways
 12.61 STAT5B STAT3 IL2RB IL2RA IL2 IL18
12
NF-kappaB Signaling 4
12.42 STAT5B STAT3 NCAM1 IL2RB IL2RA IL2
13
Human T-cell leukemia virus 1 infection 36
12.35 STAT5B IL2RB IL2RA IL2 IL15RA CSF2
14
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.3 IL2RB IL2RA IL2 IL18
15
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.28 MICA KLRK1 KLRD1 KIR2DL3 KIR2DL1 IL2
16
JAK-STAT signaling pathway (KEGG) 36
Show member pathways
 12.23 STAT5B STAT3 IL2RB IL2RA IL2 IL15RA
17
G beta-gamma signalling through PI3Kgamma 65
Show member pathways
 12.12 IL2RB IL2RA IL2 CSF2
18
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 65
12.1 MICA KLRK1 KLRD1 KIR2DL3 KIR2DL1
19
IL-2 Signaling Pathway 1
Show member pathways
 12.08 STAT5B STAT3 IL2RB IL2RA IL2
20
Th1 Differentiation Pathway 64
Show member pathways
 12.04 STAT5B STAT3 IL2 IL18
21
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.95 NCAM1 KLRK1 IL2RB IL2RA IL2 CSF2
22
Interleukin-4 and 13 signaling 65
11.92 STAT3 IL18 FASLG
23
Jak-Stat Signaling Pathway (sino) 66
11.88 STAT5B STAT3 IL2RB IL2RA IL2 IL15RA
24
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.79 IL2RA IL2 FASLG CSF2
25
Glucocorticoid receptor regulatory network 1
11.77 STAT5B IL2 CSF2
26
Dendritic Cells Developmental Lineage Pathway 64
11.72 NCAM1 IL2 CSF2
27
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.72 STAT5B IL2RB IL2RA IL2 FASLG
28
Microglia Activation During Neuroinflammation: Microglia Polarization 64
11.7 IL2 IL18 CSF2
29
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.62 IL2RB IL2RA IL2 GZMB FASLG
30
IL12-mediated signaling events 1
Show member pathways
 11.61 STAT3 IL2RB IL2RA IL2 IL18 GZMB
31
Interleukin-10 signaling 65
11.52 STAT3 IL18 CSF2
32
Granzyme Pathway 63
Show member pathways
 11.52 GZMK GZMB GZMA
33
Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway 1
11.49 STAT5B STAT3 IL2RA
34
Th2 Differentiation Pathway 64
11.48 IL2RB IL2RA IL2
35
IL-7 Signaling Pathway 1
Show member pathways
 11.48 STAT5B STAT3 IL2RA
36
Inflammatory Response Pathway 1
11.32 IL2RB IL2RA IL2
37
Immune response_IL-12 signaling pathway 22
Show member pathways
 11.26 STAT5B STAT3 IL2RA
38
IL12 signaling mediated by STAT4 1
11.26 STAT3 IL2RA IL2 IL18
39
Telomere Extension by Telomerase 63
Show member pathways
 11.23 STAT5B IL2RB IL2RA IL2
40
Innate Lymphoid Cell Differentiation Pathways 64
11.23 NCAM1 KLRK1 KLRD1 IL2RB IL2RA IL2
41
Development of pulmonary dendritic cells and macrophage subsets 1
10.8 STAT3 CSF2
Sources

GO Terms for T-Cell Large Granular Lymphocyte Leukemia

About this section

Cellular components related to T-Cell Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.5 NCAM1 MICA KLRK1 IL2RB IL2RA IL15RA
2 external side of plasma membrane GO:0009897 9.17 NCAM1 MICA KLRK1 KLRD1 IL2RB IL2RA
3 interleukin-2 receptor complex GO:0005893 9.16 IL2RB IL2RA

Biological processes related to T-Cell Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 9.88 MICA KLRK1 KLRD1 KIR2DL3 KIR2DL1
2 MAPK cascade GO:0000165 9.88 NCAM1 IL2RB IL2RA IL2 IL18 CSF2
3 positive regulation of inflammatory response GO:0050729 9.77 STAT5B IL2 IL18
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 STAT3 IL2 IL18 CSF2
5 positive regulation of interferon-gamma production GO:0032729 9.7 KLRK1 IL2 IL18
6 natural killer cell activation GO:0030101 9.67 KLRK1 IL2 IL18
7 positive regulation of activated T cell proliferation GO:0042104 9.67 STAT5B IL2RA IL2 IL18
8 cytolysis GO:0019835 9.63 MICA GZMB GZMA
9 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.62 IL18 CSF2
10 natural killer cell mediated cytotoxicity GO:0042267 9.62 MICA KLRK1 IL18 GZMB
11 regulation of regulatory T cell differentiation GO:0045589 9.61 IL2RA IL2
12 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.61 STAT5B STAT3
13 immune response GO:0006955 9.61 MICA KIR2DL3 KIR2DL1 IL2RA IL2 IL18
14 positive regulation of interleukin-17 production GO:0032740 9.6 IL2 IL18
15 interleukin-9-mediated signaling pathway GO:0038113 9.58 STAT5B STAT3
16 positive regulation of natural killer cell proliferation GO:0032819 9.58 STAT5B IL18
17 negative regulation of oxidoreductase activity GO:0051354 9.57 GZMK GZMA
18 negative regulation of lymphocyte proliferation GO:0050672 9.56 IL2RA IL2
19 interleukin-15-mediated signaling pathway GO:0035723 9.56 STAT5B STAT3 IL2RB IL15RA
20 positive regulation of tissue remodeling GO:0034105 9.55 IL2 IL18
21 neutrophil differentiation GO:0030223 9.54 LBR CSF2
22 regulation of T cell homeostatic proliferation GO:0046013 9.51 IL2RA IL2
23 interleukin-2-mediated signaling pathway GO:0038110 9.46 STAT5B IL2RB IL2RA IL2
24 cytokine-mediated signaling pathway GO:0019221 9.23 STAT5B STAT3 IL2RB IL2RA IL2 IL18

Molecular functions related to T-Cell Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.62 IL2 IL18 FASLG CSF2
2 protein binding GO:0005515 9.58 STAT5B STAT3 NCAM1 MICA LBR KLRK1
3 glucocorticoid receptor binding GO:0035259 9.37 STAT5B STAT3
4 interleukin-2 binding GO:0019976 9.26 IL2RB IL2RA
5 interleukin-15 receptor activity GO:0042010 9.16 IL2RB IL15RA
6 interleukin-2 receptor activity GO:0004911 8.96 IL2RB IL2RA
Sources

Sources for T-Cell Large Granular Lymphocyte Leukemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....